ERBE-ELEKTROMEDIZIN
6.4.2021 13:02:09 CEST | Business Wire | Press release
An investment to strengthen our operating room presence
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406005418/en/
“This acquisition reflects our determination to become a solution provider for surgeries and procedures where visualization is critical. We will offer holistic solutions, from visualization to therapy. Entering into the world of fluorescence imaging systems is the logical first step to provide the required added value to our customers", according to Christian O. Erbe, CEO & President at Erbe Elektromedizin GmbH. Maxer’s highly innovative product portfolio combined with Erbe’s energy-emitting high-tech products will allow existing unmet user needs to be addressed.
Better vision makes better surgery
Maxer’s prime innovation focus is on the development of high-end visualization. The technology delivers bright and pin-sharp multi-spectral images for NIR fluorescence-guided surgery and regular white light images. Now, Erbe will be able to offer best-in-class performance with 4K and fluorescence-guided systems in endoscopy as well as for open surgeries.
In 2020, Maxer and its partners, the Ludwig Maximilian University (LMU) Munich and the Technical University Munich (TUM), won the first prize of the German Medical Award in the “Innovation Product” category for its Atlas project. The plan is to provide the surgeon with a “GPS system” that enables the performance of advanced laparoscopic surgeries with increased surgical precision. This will help to reduce complications and risks during oncological surgeries and increase quality of patient life.
A perfect match with excellent growth prospects
The philosophy and values at Maxer are similar to Erbe’s. The company has a remarkable track record of high-tech devices in the last seven years and is perfectly positioned to master future opportunities, such as augmented reality-guided surgery. A broad minimal invasive instrument portfolio will be an ideal match to Erbe’s existing offering.
“Wonderful instruments and multi-spectral imaging systems will get access to the market through our strong sales force and our distribution partners in more than 110 countries”, says Marcus C. Felstead, CMO at Erbe.
“This acquisition will allow the company to speed up delivery of breakthrough innovations in areas of image-guided surgery,” states Shirish Joshi, Managing Director at Maxer.
Erbe was advised by ConAlliance (Mergers & Acquisitions) and RWT Reutlingen (Legal and Financial).
Our vision
The combination of electrosurgery and imaging will provide added value by processing and combining data using AI. This will lead to new treatment options and enhance patient safety. The best of both worlds.
About Maxer
Located in the Tuttlingen medical endoscopy cluster in Germany, Maxer is specialized in minimally invasive surgery (MIS). Maxer manufactures a wide range of endoscopic systems and instruments for laparoscopy, hysteroscopy, urology, pediatric surgery, arthroscopy, spine endoscopy and ENT surgery. Maxer’s core strength has been in the development of top-of-the-line visualization technologies. Maxer is partnering with the Ludwig Maximilian University (LMU) Munich and the Technical University Munich (TUM) to bring computer-assisted surgery to operating rooms.
About Erbe
Erbe Elektromedizin GmbH develops, manufactures and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryosurgery
An international network
- 15 subsidiaries in Europe, America and Asia
- 1 representative office
- Erbe is active in 110 national markets
The Erbe workforce
- Over 1,000 employees worldwide
- Some 700 of them in Germany
Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tuebingen, Germany
http://www.erbe-med.com
info@erbe-med.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005418/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom